Protagonist Therapeutics, Inc. (PTGX)
Protagonist Therapeutics, Inc. FCF to Net Income
| Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF to Net Income | 72.6% | 99.5% | 81.6% | (8.7%) | 129.6% | 55.1% | 110.3% | 86.8% | 85.5% | 89.7% |
Protagonist Therapeutics, Inc. (PTGX) FCF to Net Income comparison analysis
PTGX key stats
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
investors
worldwide
FAQ
1) What is Protagonist Therapeutics, Inc.'s FCF to Net Income?
As of today, Microsoft Corp's last 12-month FCF to Net Income is 134.2%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual FCF to Net Income for Protagonist Therapeutics, Inc. have been 88.1% over the past three years, and 89.2% over the past five years.
2) Is Protagonist Therapeutics, Inc.'s FCF to Net Income Good?
As of today, Protagonist Therapeutics, Inc.'s FCF to Net Income is 134.2%, which is higher than industry median of 84.3%. It indicates that Protagonist Therapeutics, Inc.'s FCF to Net Income is Good.